RecruitingPhase 2NCT07073417
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
A Multicenter, Randomized, Open-label, Treatment Switching Phase II Study to Evaluate the Efficacy and Safety of XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity
Sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Enrollment
160 participants
Start Date
Jul 28, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria2
- BMI≥30 kg/m2 at screening, waist circumference ≥90 cm for men and ≥85 cm for women.
- Weight change of less than 5% within 3 months prior to screening (self-reported).
Exclusion Criteria6
- Diagnosis of obesity due to endocrine disorders or a single gene mutation, including but not limited to hypothalamic obesity, pituitary obesity, Cushing's syndrome, hypothyroidic obesity (except for those with normal thyroid function at screening and expected to remain unchanged throughout the trial period after at least 3 months of thyroid hormone replacement therapy), insulinoma, acromegaly.
- History of bariatric surgery or planning to undergo bariatric surgery or use other weight-loss drugs or devices during the trial (except acupuncture for weight loss, liposuction, or abdominal fat removal for more than one year before screening; Except the removal or expulsion of the airbag in the stomach for more than 1 year before screening.
- Diagnosis with any type of diabetes (except gestational diabetes).
- Have used any weight-loss drugs, hypoglycemic drugs, or drugs that may cause significant weight gain within 3 months prior to screening.
- History of acute or chronic pancreatitis or pancreatic injury, history of symptomatic gallbladder disease (except cholecystectomy).
- History of clinically significant gastric emptying abnormalities, such as gastroparesis or gastric outlet obstruction.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGXW003 injection
Subcutaneous injection
DRUGsemaglutide injection
Subcutaneous injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07073417
Related Trials
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
NCT011434543 locations
Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention
NCT019277831 location
Investigating the Impact of Obesity on Pubertal Development in Girls
NCT025836461 location
Diabetes and Heart Disease Risk in Blacks
NCT000018531 location
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
NCT0728497932 locations